Functional remodeling of macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma

被引：0
|
作者：
Han, Zhen [1 ,5 ]
Su, Ching-Yu [1 ,5 ]
Wu, Xiwei [2 ,5 ]
Qin, Hanjun [2 ,5 ]
Zain, Jasmine [3 ]
Rosen, Steven T. [3 ,5 ]
Querfeld, Christiane [1 ,3 ,4 ,5 ]
机构：
[1] City Hope Natl Med Ctr, Div Dermatol, Duarte, CA USA
[2] City Hope Natl Med Ctr, Dept Mol & Cellular Biol, Duarte, CA USA
[3] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
[4] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA USA
[5] Beckman Res Inst, Duarte, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2021年 / 156卷
关键词：
Tumor microenvironment; PD1/PD-L1; blockade; lenalidomide; macrophage remodeling; CTCL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prec-O2-04
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [41] Hair RepigmentationWith Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis
    Sebaratnam, Deshan Frank
    Rodriguez Bandera, Ana Isabel
    Lowe, Patricia Margaret
    JAMA DERMATOLOGY, 2018, 154 (01) : 112 - 113
  • [42] Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
    Swaika, Abhisek
    Hammond, William A.
    Joseph, Richard W.
    MOLECULAR IMMUNOLOGY, 2015, 67 (02) : 4 - 17
  • [43] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
    Wang, Sarah
    Sun, Kaiming
    Xiao, Yonghong
    Feng, Bin
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing
    CANCER RESEARCH, 2018, 78 (13)
  • [44] New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
    Chen, Cheng
    Huang, Jian-An
    EUROPEAN JOURNAL OF INFLAMMATION, 2016, 14 (01) : 61 - 65
  • [45] Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR mutant NSCLC
    Tu, Eric
    McGlinchey, Kelly
    Lazdun, Yelena
    Kurasawa, James
    Wilson, Susan
    Wetzel, Leslie
    Coffman, Karen
    Cooper, Zachary
    Streicher, Katie
    CANCER RESEARCH, 2020, 80 (16)
  • [46] Adjuvant effect of anti-PD-L1 in boosting HER2-targeted T cell adoptive immunotherapy
    Xia, Yang
    Hu, Yangyang
    Wang, Yi
    Bao, Yangyi
    Dai, Fu
    Huang, Shiang
    Hurt, Elaine
    Hollingsworth, Robert E.
    Thakur, Archana
    Lum, Lawrence
    Chang, Alfred E.
    Wicha, Max S.
    Li, Qiao
    CANCER RESEARCH, 2016, 76
  • [47] Anti-PD-L1 inhibitor durvalumab in bladder cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (07): : E275 - E275
  • [48] Pulmonary Sarcoidosis Associated With Anti-Pd-L1 Therapy
    Balestra, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [49] Anti-PD-L1 therapy: patient selection is important
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2016, 13 (3) : 134 - 134
  • [50] Product review on the Anti-PD-L1 antibody atezolizumab
    Shah, Neil J.
    Kelly, William J.
    Liu, Stephen V.
    Choquette, Karin
    Spira, Alexander
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (02) : 269 - 276
12345